Dual CBP/p300 and BRD4 bromodomain inhibitor (IC50
values are 0.65 and 1.5 μ
M for CBP and BRD4 respectively). Downregulates IL-6
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities.
Chekler et al.